Opinion · 1 Dec 2025
EditorialPublished 29 Jul 2025
Immune Checkpoints: Targets, Resistance, and Future Therapies
Department of Immunology UNAM, México
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Immune checkpoint inhibitors targeting pathways like PD-1/PD-L1 and CTLA-4 have revolutionized cancer immunotherapy.These pathways regulate T cell responses, and their blockade can restore anti-tumor immunity. Challenges include tumor microenvironment modulation, resistance mechanisms, and the need for better predictive biomarkers. Emerging checkpoints and the interplayof innate and adaptive immunity, cellular metabolism, and the gut microbiome are critical areas of investigation for optimizingtherapeutic efficacy.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Immunology: Current Research.
Editorial · 1 Dec 2025
Auto-inflammatory Disorders: Genetic Causes and Targeted Therapies
Editorial · 1 Dec 2025
Host-Parasite Immunological Arena: An Intricate Balance
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunology: Current Research
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Dr. Pablo Ruiz”
